Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanfacine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.93 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.93 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | HTR1A | P08908 | 1/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | MAOA | P21397 | 1/20 | 0.93 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.93 |
| ▸ | HTR2A | P28223 | 1/20 | 0.93 |
| ▸ | HTR2C | P28335 | 1/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | DRD3 | P35462 | 1/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.93 |
| ▸ | HTR2B | P41595 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanfacine SCHEMBL35095 | 0.96 | ADRA2A (1.00) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| Guanfacine SCHEMBL15603414 | 0.95 | ADRA2A (1.00) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL11391966 | 0.80 | KMT2A (0.71) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| Guanfacine SCHEMBL28172481 | 0.79 | KMT2A (0.68) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL31231111 | 0.78 | ADRA2A (0.68) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL439567 | 0.78 | KMT2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL439566 | 0.78 | KMT2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10918195 | 0.77 | ADRA2A (0.67) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10921192 | 0.77 | ADRA2A (0.66) | ADRA2AKMT2AMEN1LMNACYP3A4 | |
| SCHEMBL10308390 | 0.76 | KMT2A (0.65) | ADRA2AKMT2AMEN1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395749-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-02-04 | — | — | US | disclosed |
| CN-111465392-B | Transdermal therapeutic system for transdermal administration of guanfacine comprising a silicone polymer | 罗曼治疗系统股份公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-12-17 | — | — | US | disclosed |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-11-14 | — | — | US | disclosed |
| US-12048770-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-07-30 | — | — | US | disclosed |
| EP-4395749-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS Lohmann Therapie-Systeme AG (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-111447926-B | Transdermal therapeutic system for transdermal administration of guanfacine comprising at least one additive | 罗曼治疗系统股份公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117897144-A | Transdermal therapeutic system for transdermal administration of guanfacine comprising guanfacine and a monocarboxylic acid | LTS罗曼治疗系统股份公司 | 2024-04-16 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009143367-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | PDE2A, PDE3A, PDE3B | ADRA2A 33/4885ADRA2B 35/4885ADRA2C 39/4885 |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | GUCY1A2, PDE2A, PDE3A | ADRA2A 16/4885ADRA2B 18/4885ADRA2C 12/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRA2A 815/4885ADRA2B 551/4885ADRA2C 1073/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | ADRA2A 7/4885ADRA2B 5/4885ADRA2C 8/4885 |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | GUCY1A2, MTHFD1, FPGS | ADRA2A 52/4885ADRA2B 187/4885ADRA2C 25/4885 |
| US-12048770-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer | PDE2A, PDE3A, GUCY1A2 | ADRA2A 15/4885ADRA2B 37/4885ADRA2C 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.